TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4037255

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride 1 mg/ml
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride 5 mg/ml
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride 10 mg/ml
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride (all concentrations)
Number of subjects: 5
Study: 31593592

Group type: COMPARATOR
Intervention: Engagement in contemplation group vs. pre‐contemplation group
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Individual degree centrality (comments and likes)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Group-based social media intervention
Number of subjects: 251
Study: 31304890

Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST) during aplasia, consisting of five 1-hour individual sessions starting 2 days before HSCT.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (CG) without PST.
Number of subjects: 91
Study: 29480874

Group type: EXPERIMENTAL
Intervention: EVIDENT 3 application with smartphone and smartband for 3 months
Number of subjects: 700

Group type: COMPARATOR
Intervention: Traditional primary care lifestyle counseling
Number of subjects: 700
Study: 26839144

Group type: EXPERIMENTAL
Intervention: Abituzumab 750 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Abituzumab 1,500 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Abituzumab
Number of subjects: 180
Study: 25280410

Group type: EXPERIMENTAL
Intervention: Fructose supplementation (120 g/d for 3 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucose solution (control)
Number of subjects: 10
Study: 23236449

Group type: EXPERIMENTAL
Intervention: Low intensity exercise (40% VO2peak)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High intensity exercise (80% VO2peak)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 8
Study: 19357861

Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol
Number of subjects: 235

Group type: COMPARATOR
Intervention: GnRH agonist protocol
Number of subjects: 235
Study: 18066449

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Ventilation with two pressure levels (PEEP + SP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: BiPAP
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: NIV application
Number of subjects: 57
Study: 16295154

Group type: EXPERIMENTAL
Intervention: Usual care plus 3 hours contact with a pediatric nurse practitioner (PNP) for counseling, instruction, and assistance with implementation of the recommended treatment plan
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (1-hour consultation session and written treatment plan)
Number of subjects: 31
Study: 12505250

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 5804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5804
Study: 9529267

Group type: EXPERIMENTAL
Intervention: Single-chamber atrial pacing
Number of subjects: 225

Group type: COMPARATOR
Intervention: Single-chamber ventricular pacing
Number of subjects: 225
Study: 7639973

Group type: EXPERIMENTAL
Intervention: Behavioural interventions for HIV/AIDS prevention
Number of subjects: 68
Study: 2136939

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 7
Study: 323454

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Picloxydine mouthwash (higher concentration)
Number of subjects: 0
Study: 30724574

Group type: EXPERIMENTAL
Intervention: Goal-Oriented Attentional Self-Regulation training (GOALS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Brain Health Education program (BHE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 30217118

Group type: EXPERIMENTAL
Intervention: Denosumab alone
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Denosumab plus teriparatide
Number of subjects: 47
Study: 28395131

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate containing 50 mg elemental zinc daily for 12 weeks)
Number of subjects: 60
Study: 24916837

Group type: EXPERIMENTAL
Intervention: Path analysis model
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Time spent processing the cancer experience
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Cancer worry
Number of subjects: 2524
Study: 23686379

Group type: EXPERIMENTAL
Intervention: Standard of care + daily CP mouth rinses (n=27)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care (n=31)
Number of subjects: 60
Study: 22139337

Group type: EXPERIMENTAL
Intervention: Betacarotene (BC) group supplemented daily with 50 mg of BC (n=9; LW: 17.3±1.0 kg; BCS: 3.34±0.12)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CONT; n=8; LW: 16.1±1.0 kg; BCS=3.17±0.12)
Number of subjects: 17
Study: 19109408

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg in pellet form
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no orlistat)
Number of subjects: 0
Study: 17003088

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Subcutaneous insulin (sc insulin)
Number of subjects: 226
Study: 15285598

Group type: EXPERIMENTAL
Intervention: Controlled scientific causal thinking simulation
Number of subjects: 0
Study: 11261319

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g once daily plus tobramycin 5 mg/kg
Number of subjects: 114

Group type: COMPARATOR
Intervention: Cefotaxime 2 g three times daily plus tobramycin 5 mg/kg
Number of subjects: 114
Study: 9249099

Group type: EXPERIMENTAL
Intervention: 400 mg intravenous ibuprofen
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 8034237

Group type: EXPERIMENTAL
Intervention: 5,000 IU unfractionated (UF) heparin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1,500 activated partial thromboplastin time units low molecular mass (LMM) heparin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2894979

Group type: EXPERIMENTAL
Intervention: Felodipine (5, 10, 20 mg bid)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prazosin (1, 2, 4 mg bid)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 80 degrees tilt
Number of subjects: 22
Study: 29490090

Group type: EXPERIMENTAL
Intervention: Common bean flour
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Roasted cowpea
Number of subjects: 331

Group type: COMPARATOR
Intervention: Corn-soy blend (control)
Number of subjects: 331
Study: 28069096

Group type: EXPERIMENTAL
Intervention: 1-day simulation course
Number of subjects: 37
Study: 26512149

Group type: EXPERIMENTAL
Intervention: Garcin tablets 1,500 mg daily for 7 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: Fluconazole tablets 150 mg daily for 7 days
Number of subjects: 110
Study: 23221480

Group type: EXPERIMENTAL
Intervention: Combination therapy with tamsulosin (0.4 mg) and fesoterodine extended-release
Number of subjects: 47

Group type: COMPARATOR
Intervention: Single administration of tamsulosin (0.4 mg)
Number of subjects: 47
Study: 21891972

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg IV infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17368873

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (150mg/day of CoQ(10) for four weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 40
Study: 16868359

Group type: EXPERIMENTAL
Intervention: 900 mg dried garlic powder
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12624611

Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle intervention in a rehabilitation centre for 12 months
Number of subjects: 731

Group type: COMPARATOR
Intervention: Usual care in an occupational or primary health-care centre for 12 months
Number of subjects: 731
Study: 10487669

Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration at 1700 h
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration at 0500 h
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 9
Study: 8579029

Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 15
Study: 1859762

Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg kg‐1
Number of subjects: 0
Study: 6811237

Group type: EXPERIMENTAL
Intervention: 20 g human immunoglobulin i.v. over four months
Number of subjects: 98

Group type: COMPARATOR
Intervention: Blood transfusions (control group) averaging 4.4 units per patient
Number of subjects: 98

Group type: COMPARATOR
Intervention: Blood transfusions (control group)
Number of subjects: 98
Study: 31196147

Group type: EXPERIMENTAL
Intervention: Single bout of aerobic exercise for 30 minutes at 80% individual anaerobic threshold
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (sitting and reading for 30 minutes)
Number of subjects: 92
Study: 28902927

Group type: EXPERIMENTAL
Intervention: 20 min of exercise performed at 120% of lactate threshold (120%LT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 20 min of exercise performed at 80% of lactate threshold (80%LT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 11
Study: 25585514

Group type: EXPERIMENTAL
Intervention: Effective-LEDT
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo-1-LEDT
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo-2-LEDT
Number of subjects: 1
Study: 23497465

Group type: EXPERIMENTAL
Intervention: Best medical care plus intermittent pneumatic compression (IPC)
Number of subjects: 2876

Group type: COMPARATOR
Intervention: Best medical care
Number of subjects: 2876

Group type: EXPERIMENTAL
Intervention: Best medical care plus IPC
Number of subjects: 2876
Study: 21310051

Group type: EXPERIMENTAL
Intervention: ondansetron syrup (0.15 mg/Kg of body weight)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: domperidone syrup (0.5 mg/Kg of body weight)
Number of subjects: 540

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 540
Study: 19797255

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: NYHA class >II
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Spontaneous or inducible VT as indication for ICD therapy
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Use of amiodarone
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Renal failure
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Use of digitalis
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Use of diuretics
Number of subjects: 822
Study: 16881807

Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine and 0.025% fluoride mouthrinse
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 0.1% cetylpyridiniumchloride and 0.025% fluoride mouthrinse
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Dental floss
Number of subjects: 156

Group type: COMPARATOR
Intervention: Toothbrushing only
Number of subjects: 156
Study: 14709577

Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 11886028

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 21
Study: 9462489

Group type: EXPERIMENTAL
Intervention: 11 mg/d transdermal nicotine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 22 mg/d transdermal nicotine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 44 mg/d transdermal nicotine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Continuous abstainers (21 subjects)
Number of subjects: 70
Study: 7832596

Group type: EXPERIMENTAL
Intervention: Management of behavioral manifestations of dementia
Number of subjects: 0
Study: 1970466

Group type: EXPERIMENTAL
Intervention: Zidovudine, 200 mg orally every 4 hours
Number of subjects: 711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study: 154492

Group type: EXPERIMENTAL
Intervention: Ipratropium (80 microgram)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6861859

Group type: EXPERIMENTAL
Intervention: Slow-release furosemide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard formulation of furosemide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sodium excretion
Number of subjects: 18
Study: 30194887

Group type: EXPERIMENTAL
Intervention: Fortified mother's milk (FHM)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Preterm formula (PF)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Unfortified mother's milk (UHM)
Number of subjects: 281
Study: 30044241

Group type: EXPERIMENTAL
Intervention: Caffeine citrate (15mg/kg, equivalent to 7.5mg/kg of caffeine base)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Number of subjects: 8
Study: 27903345

Group type: EXPERIMENTAL
Intervention: 70 kV CT angiography with 0.8 ml/kg contrast agent
Number of subjects: 200

Group type: COMPARATOR
Intervention: 120 kV CT angiography with 100 ml contrast agent
Number of subjects: 200
Study: 25445073

Group type: EXPERIMENTAL
Intervention: Exposure-based therapy with safety behavior assessment
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Texas Safety Maneuver Scale (TSMS)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Exposure-based therapy
Number of subjects: 268
Study: 22178539

Group type: EXPERIMENTAL
Intervention: Neridronate 12.5 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Neridronate 25 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Neridronate 50 mg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 21130385

Group type: EXPERIMENTAL
Intervention: Omalizumab (minimum, 0.016 mg/kg/IU (IgE/mL) every 4 weeks)
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 1071
Study: 18637638

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15383747

Group type: EXPERIMENTAL
Intervention: Rivastigmine (6-12 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 44
Study: 12413703

Group type: EXPERIMENTAL
Intervention: Phytodrug (QG-5) from guava leaves, 500 mg capsules administered every 8 hours for 3 days
Number of subjects: 50
Study: 10527973

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) plus paracervical block (PCB)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Alfentanil plus paracervical block (PCB)
Number of subjects: 150
Study: 8846250

Group type: EXPERIMENTAL
Intervention: 0.5% timolol drops
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 37
Study: 2109467

Group type: EXPERIMENTAL
Intervention: Midazolam for anxiety relief during radial keratotomy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Midazolam with low doses of phenoperidine for sedation and amnesia during cataract surgery
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Midazolam combined with fentanyl and vecuronium for general anaesthesia in elderly patients
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Midazolam to decrease intraocular pressure
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Flumazenil to antagonise midazolam effects
Number of subjects: 3
Study: 7247000

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg piritramide
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.003 mg/kg fentanyl
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Extracorporeal circulation
Number of subjects: 36
Study: 31542090

Group type: EXPERIMENTAL
Intervention: Taiwan Smoker's Helpline (TSH)
Number of subjects: 68
Study: 29131352

Group type: EXPERIMENTAL
Intervention: Intravenous ethanol infusion at 100 mg%
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intravenous ethanol infusion at higher doses
Number of subjects: 93
Study: 26291199

Group type: EXPERIMENTAL
Intervention: Selexipag (compound 26a)
Number of subjects: 0
Study: 24831989

Group type: EXPERIMENTAL
Intervention: Intensified insulin-based glycaemic control for at least 3 months
Number of subjects: 620

Group type: COMPARATOR
Intervention: Conventional glucose-lowering treatment (Control)
Number of subjects: 620
Study: 22628108

Group type: EXPERIMENTAL
Intervention: 3 days per week training frequency
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5 days per week training frequency
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both training frequencies (3 days and 5 days per week)
Number of subjects: 12
Study: 19361029

Group type: EXPERIMENTAL
Intervention: Remote-mounted perfusion system
Number of subjects: 4
Study: 17324253

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine acupuncture-care and self-care (10 sessions over 12 weeks)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Self-care only (control group)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine acupuncture-care and self-care
Number of subjects: 286
Study: 15364757

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Hospitalization in the prior 3 months
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: General QOL measures
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Disease-specific QOL measures
Number of subjects: 1218
Study: 11445753

Group type: EXPERIMENTAL
Intervention: Exercise treatment group, met three times/week throughout the study
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Exercise treatment group
Number of subjects: 308
Study: 9692123

Group type: EXPERIMENTAL
Intervention: formoterol 12 micrograms b.i.d.
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: formoterol 24 micrograms b.i.d.
Number of subjects: 262

Group type: COMPARATOR
Intervention: salbutamol 400 micrograms q.i.d.
Number of subjects: 262
Study: 8209977

Group type: EXPERIMENTAL
Intervention: Continuous flow continuous positive airways pressure system
Number of subjects: 10

Group type: COMPARATOR
Intervention: Demand valve system of the Engstrom Erica ventilator
Number of subjects: 10
Study: 3791601

Group type: EXPERIMENTAL
Intervention: timolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 31996334

Group type: EXPERIMENTAL
Intervention: Clipping of aneurysms aided by transit time flowmetry
Number of subjects: 0
Study: 31359357

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 160 mg daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 25919112

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (1000 μg daily) for 4 weeks
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: rs7772821 (T>G) polymorphism
Number of subjects: 246
Study: 23414637

Group type: EXPERIMENTAL
Intervention: Volunteer coaching program including a coach and reminders by well-trained volunteers, three home visits and five telephone calls over a two-month period
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Volunteer coaching program
Number of subjects: 62
Study: 22194988

Group type: EXPERIMENTAL
Intervention: Low-dose flutamide, metformin, and pioglitazone in combination with an estro-progestagen
Number of subjects: 0
Study: 19348959

Group type: EXPERIMENTAL
Intervention: Sleep (overnight sleep)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daytime wakefulness (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nap study (sleep)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep, slow-wave sleep (SWS)
Number of subjects: 0
Study: 16521013

Group type: EXPERIMENTAL
Intervention: Posterior soft tissue repair
Number of subjects: 33

Group type: COMPARATOR
Intervention: No posterior soft tissue repair
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (with and without posterior soft tissue repair)
Number of subjects: 33
Study: 15340334

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 11169056

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2a 6 million units three times weekly plus ribavirin 14 mg/kg per day (n=93)
Number of subjects: 185
Study: 9166306

Group type: EXPERIMENTAL
Intervention: Fetal monitor cystometrogram
Number of subjects: 66

Group type: COMPARATOR
Intervention: Multichannel electronic cystometer
Number of subjects: 66
Study: 8250106

Group type: EXPERIMENTAL
Intervention: Quinine (17 mg/kg over 4.5 hr)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Quinine alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (12.5 mg intramuscularly)
Number of subjects: 12
Study: 3903529

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30230694

Group type: EXPERIMENTAL
Intervention: Oral cabotegravir 30 mg after a high-fat meal (∼53% fat, ∼870 kcal)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral cabotegravir 30 mg after fasting
Number of subjects: 24
Study: 27547853

Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training (CAT) guide
Number of subjects: 17

Group type: COMPARATOR
Intervention: Support-manual
Number of subjects: 17